nmra (NMRA) Analyst & Key Data

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

6

Hold

1

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score4.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.04

Median Target+508.65%

$6.33

Potential upside vs current price

DCF Value+5.47%

$1.10

Potential upside vs current price

Current Stock Price

$1.04

Median Target+508.65%

$6.33

Potential upside vs current price

DCF Value+5.47%

$1.10

Potential upside vs current price

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

6

Hold

1

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score4.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$1.04

Median Target+508.65%

$6.33

Potential upside vs current price

DCF Value+5.47%

$1.10

Potential upside vs current price

Current Stock Price

$1.04

Median Target+508.65%

$6.33

Potential upside vs current price

DCF Value+5.47%

$1.10

Potential upside vs current price

Neumora Therapeutics, Inc. Common Stock